Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

24.37 +0.31 (+1.29%)
Streaming Delayed Price Updated: 10:42 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
3 Biotech Companies to Watch in 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year. 
Via InvestorPlace
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average. 
Via Investor's Business Daily
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
From Genmab A/S
Via Business Wire
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
3 Hot Stocks That Could Live Up to Their Lofty Valuations
These companies have long runways of growth ahead 
Via The Motley Fool
Is AbbVie Stock a Buy Now?
The pharmaceutical company prepared well as Humira approaches its patent cliff next year. 
Via The Motley Fool
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink
You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark
In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday. 
Via Investor's Business Daily
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before. 
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. 
Via Investor's Business Daily
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73. 
Via Investor's Business Daily
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
 
Via Benzinga
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. 
Via Investor's Business Daily
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier. 
Via Investor's Business Daily
Golden Cross Appears Before Genmab Investors
If history is any guide, there may be good fortune ahead for shares of Genmab (NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.